Shares of Aptose Biosciences (APS) were revisited by a Wall Street analyst today. Analyst Jotin Marango from Roth Capital remains bullish on the stock and has a C$7 price target.
Marango noted:
“We remain bullish on the value of the cluster-specific kinase inhibitor CG’806, as it heads into an IND in 1Q19. We believe that the upcoming Phase 1 program covering both myeloid and lymphoid malignancy will cast an appropriately wide net, and are encouraged by multiple potential target disease subpopulations emerging from the preclinical data.”
According to TipRanks.com, Marango is ranked 0 out of 5 stars with an average return of -14.0% and a 23.2% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Cyclacel Pharmaceuticals.
Read also: MYOS RENS Technology (MYOS) Stock Fires Up to the Roof; Here’s Why
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aptose Biosciences with a C$7 average price target, implying a 138.1% upside from current levels. In a report issued on December 3, H.C. Wainwright also reiterated a Buy rating on the stock.
.
Aptose Biosciences’ market cap is currently C$103.3M and has a P/E ratio of 0. The company has a Price to Book ratio of 5.74.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG’806 a non-covalent small molecule therapeutic agent.
The company’s shares closed on Wednesday at C$2.94.
